ProCE Banner Activity

Insight on Key New Data From the 2023 ESMO Annual Congress Informing Treatment for Endometrial, Ovarian, and Cervical Cancers

Conference Coverage
Clinical Thought

In this commentary, Isabelle Ray-Coquard, MD, PhD, and Ana Oaknin, MD, PhD, share their thoughts on key new data for gynecologic cancers presented at the 2023 ESMO Congress, including new clinical trial results for endometrial, ovarian, and cervical cancers.

Released: November 27, 2023

Share

Faculty

Ana Oaknin

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Prof Isabelle Ray-Coquard

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This educational activity is supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp, Novocure, Genmab and Seagen.

AstraZeneca

Genmab

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Novocure

Seagen

Disclosure

Primary Author

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Ana Oaknin, MD, PhD: consultant/advisor/speaker: Agenus, AstraZeneca, Clovis Oncology, Corcept Therapeutics, Deciphera Pharmaceuticals, Eisai, EMD Serono, Exelisis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Itheos, Merck Sharp & Dohme de España, Mersana Therapeutics, NovoCure, OneXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Sattucklabs, Seagen and Sutro Biopharma.

Prof Isabelle Ray-Coquard, MD, PhD

President of the Gineco Group
Centre Leon Bérard
Laboratoire RESHAPE u1290
Université Claude Bernard Lyon Est
Lyon, France

Isabelle Ray-Coquard, MD, PhD: consultant/advisor/speaker: Agenus, Amgen, AdaptImmune, Agenus, AstraZeneca, Bristol Myers Squibb, Clovis Oncology, Daiichi Sankyo, Deciphera, Eisai, Exelixis, F. Hoffmann-La Roche, Genmab, GlaxoSmithKline, ImmunoGen, Merck Sharp & Dohme, Mersana Therapeutics, NovoCure, OneXerna Therapeutics, PharmaMar, Regeneron, SA Pharma, Seagen, Sutro Biopharma.